Drug data last refreshed 2h ago · AI intelligence enriched 2w ago
CYCLOCORT is a topical ointment containing a small-molecule corticosteroid approved in 1981 for dermatological inflammatory conditions. The precise indication profile is not specified in available data, but topical corticosteroids are typically used to treat eczema, psoriasis, dermatitis, and other inflammatory skin disorders. The mechanism of action involves anti-inflammatory and immunosuppressive activity through glucocorticoid receptor binding.
Approaching loss of exclusivity with moderate competitive pressure (30/100), suggesting a mature product with declining team investment and focus shifting toward retention strategies.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
CYCLOCORT represents a mature franchise with zero linked job openings, indicating minimal hiring and team contraction. Career growth is limited; positions emphasize cost management, generic defense, and market retention rather than innovation or expansion.
Worked on CYCLOCORT at Astellas? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.